echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The fifth batch of domestic agents to choose high-quality products can not be missed!

    The fifth batch of domestic agents to choose high-quality products can not be missed!

    • Last Update: 2021-08-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News on August 2nd that the fifth batch of national collections has been settled, and the provinces have successively issued documents to implement the results of the selection
    .
    On July 20, the Jiangxi Provincial Medical Security Bureau issued the "Notice on Launching the Fifth Batch of National-Organized Drug Centralized Procurement of Drugs Related to Online Procurement", requiring relevant selected companies to declare information online and confirm their distribution relationships
    .

     
    From the first batch to the fifth batch, Guocai has 218 products.
    There are a few products with good market expectations, policies, and volume in the first batch.
    The second to fourth batches are not many.
    The fifth batch is still There are a lot of them.
    There are at least 15 products that can be operated in each province without self-operated products
    .
     
    In recent years, the pressure on agents has been relatively high, and this is also true for most companies
    .
    Being able to "pass through the barriers" in the national procurement process gives the product a good market opportunity, and companies must choose high-quality partners
    .
    For agents, this is a once-in-a-lifetime opportunity, but many agents seem to be more than enthusiastic and insufficiently prepared
    .
     
    A rare opportunity
     
    1.
    National procurement + provincial/union belt volume + price linkage + "red, yellow and green" (the price of each province is divided
    .
    The red line is too high to enter the hospital; the yellow line can be used, but it must be monitored; the green line is not restricted) There must be a quantity expectation of 490 varieties.
    The provincial/union belt quantity will adopt an average of 20+ varieties in 2020, an average of 40+ varieties in the province/union in 2021, and 200+ varieties in the Guangdong Grand Alliance.
    The accumulation of this order of magnitude will result in increasingly stringent prices.
    "Assault" blind spots make it difficult for most products to have conventional policies
    .

     
      The quantity of various concepts, whether it is national or non-over-reviewed provincial/union mining, is a general trend within a period of time, and the future fate of similar products can be foreseen
    .
     
      Under this trend, there are fewer and fewer products that can have high-quality cooperation opportunities, but the market is still there, and there are no fewer agents
    .
    Whether the present is an opportunity depends not only on the present, but also on the future trend
    .

     
      2.
    The timeliness of making new medicines for old medicines.
    It is undeniable that new medicines for old medicines (classic return) can bring many opportunities, but except for products that can enter the list of shortage medicines, the market opportunities for other products are temporary
    .
     
      This temporaryity can be long or short, and it is difficult for these products to become mainstream in the market
    .
    Although compared with innovative drugs, these products have low cost and high controllability, but there are fewer and fewer operability products, and some products "play and crash"
    .

     
      The old medicines are newly made from chemical medicines to Chinese patent medicines, from the products of the 1990s to the 1980s, and now they are digging for the products of the 1960s and 1970s.
    If they continue to dig, they will go back and forth
    .
     
      3.
    The inaccessibility of innovation Most of the products of leading companies and innovative companies are self-operated
    .
    From the agency's point of view, the availability of innovative products is getting lower and lower.
    After all, innovative drugs are not something you can do if you want to
    .

     
      At present, there are not many innovative products in the chemical medicine category that have agency attributes.
    Even if the products approved every year are in the second and third categories, few companies do the agency model, and even if they do, it is a terminal cooperation model
    .
     
      With large investment in innovation, high risks, long cycles, and low probability, once there is a high-quality track, with the blessing of the capital side, it will soon become a "red sea"
    .
    From the perspectives of dosage form, compound prescription, route of administration, adding device, etc.
    , the endless "seventy-two changes" have almost nothing to do with small businesses
    .

     
      4.
    Difficulty of Chinese patent medicines.
    Change some Chinese patent medicines to beautiful packaging, circle a bunch of indications, and list the advantages of the market, but there are really not many who can turn out the waves.
    They are more immersed in their own "ideal country.
    " Inside
    .
     
      Most Chinese patent medicines are effective, with a wide range of indications, many manufacturers, optimistic market prospects, policy support, adequate Chinese medicine theory, and cruel market performance speaks for itself.
    Among the tens of thousands of approvals, those who stand out are only rare
    .
     
      To sum up, the high-quality cooperation bid won by the national mining company is definitely a good opportunity and should not be missed
    .
     
      Agent Baitai
     
      It is precisely because the fifth batch of Guocai Ke's high-quality cooperation products are not bad, the market has rippled, so that a lot of agents have rekindled the fire of hope, and they have shown everything
    .
     
      1.
    Tiger type (strong strength, understanding of the market, and macro vision) These agents often become the "head distributors" of the market in a certain field (treatment), holding a lot of products, and there are many large products.
    One of the goals that agency enterprises hope to cooperate with
    .
     
      They have a wealth of experience, strong business capabilities, a direct sales team and a distribution network, understand the general market trends, and can judge the product’s "vitality + market power"; they have a deep understanding of the category, and consider the terminal rational use of drugs, DRGs, and medication guidelines , Product features, instead of just talking about "who I know" and "how much space is there"; dare to make a move, dare to make a price, and know how to grasp the added value that high-quality cooperative products can bring under the opportunity of national sourcing.
    This is not just a matter of profit.
    But it can bring a series of market resources and opportunities to dominate in a certain field; data, capital, and market are fully prepared, full of sincerity, reasonable and well-founded
    .
     
      2.
    Black bear type These agents have certain or very strong strength, but they have lived in the past and have not yet emerged from the "comfort zone"
    .
     
      Their minds always revolve around 4 times space and 5 times space.
    When you talk about 3 times space, his expression reveals the following meaning: "With this little space, you still dare to talk to me for business? You don't know me.
    Don’t make varieties that are not 4 times larger? Don’t pick up varieties that are not over 100 million?"
     
      You talk to him about major trends, national policies, end-use drugs, product characteristics, and similar patterns.
    He just said: "High space can overwhelm everything
    .
    "
     
      As soon as the manufacturer wanted to talk about the situation of Guocai, he said to you: "I know, I have received a lot of Guodian products, and the space is good.
    Then, the terminal is not as you think, and the high-multiplier is not ideal.
    You can't do this
    .
    "
     
      They want money and money, and some people, but there is no way to talk with you on the same channel.
    Some things must be experienced, deeply experienced, and experienced.
    Only after suffering a loss can the three views be consistent
    .
    The typical "hibernation period" of such agents is too long, and some tiger-type agents have already occupied the territory.
    Judging from the general market trend, he has not yet woken up
    .

     
      3.
    Fish-catching type.
    This kind of agent is based on the principle of "there is no jujube but one shot".
    When encountering people who don't understand the market, they bombarded and talked about the little manager, and they basically succeeded.

    .
     
      They lack a macro understanding of the product and a lack of in-depth understanding of the market.
    When asked how big the product can be in a certain market, he said: "It's a lot, but a lot
    .
    " In contrast, he said: "Whose products are well sold and sold well
    .
    "
     
      Such agents know a little bit about the market, products, and trends, but they don't pay enough attention to their psychology and preparation
    .
     
      4.
    Peacock type.
    Such agents like to display "feathers"
    .
    The bigwigs of the rivers and lakes all have a glorious history.
    Speaking of the past, they can come back to life, and they are brilliant
    .
    Nowadays, market information is basically transparent, and there may be some information asymmetry, but there is no information that cannot be asked.
    The tiger has never been called a hunting dog, and the eagle has never been mistaken for a squab
    .
    Behind the beauty is real strength, not history
    .
     
      5.
    Wild wolf type.
    This kind of agents generally take part of the area or take part of the terminal, follow closely, bite to death, sincere, have the strength in the area, and have the vision of the provincial agent
    .
     
      After all, most of the agents are regional agents, and the provincial generations are also divided into levels.
    The first grade with annual sales of more than 1 billion yuan, the first grade with annual sales of more than 300 million yuan, the overall scale of less than 100 million provincial agents can only be called Total generation
    .
     
      However, among the provincial generations with annual sales of 100 million yuan, the new generation (post-90s and some post-80s) are absolutely motivated.
    They have a yearning for medicine and freedom of wealth.
    This is also when many companies choose agents .
    I prefer to talk more about the reasons with the new generation
    .
     
      Time never comes
     
      The era of meager profit has come for several years
    .
    Starting in 2019, how many varieties of the top 500 catalogs have not been included in the collection? Under the Guangdong Grand Alliance mechanism (combination of dosage forms and specifications), how much room does Group B have? How many products with reference preparations under the country still have a high-space policy? How long is the life cycle of a product that is not referenced or not evaluated? The market is still that market, and the product is still that product, but the opportunity is no longer the original opportunity
    .

     
      Varieties such as fosfomycin sodium, oxacillin, and mezacillin have been rapidly emerging, and markets such as cefminox and cefotaxime are responding quickly, but there are still several products that are not included in the national procurement, even if they are not in the fifth batch.
    In the catalog, the sixth and seventh batches may still be included.
    When the quantity is large, local and alliances will still be included.
    "Those who do not break the situation will still exist" (the monopoly will not be broken, and there will still be companies entering afterwards.
    Monopoly situation)
    .
     
      At this stage, acting as an agent for a non-exclusive product, if it can cover more than 40% of the terminals, it is considered a fairy-level figure of the agent
    .
    For Guocai products, if 50% of the quota is exempted from development, 30% of new accounts will reach the limit
    .
    Some specialized products and products with strong departmental characteristics can basically have more than 70% to 90% of the reported volume (development-free), and what the agent has to do is nothing more than an increase
    .
    Compared with each other, which one is easier?
     
      It can be understood that if there is a 10% space for the agent’s policy for national procurement products, it is equivalent to 20% under normal conditions; the national procurement policy gives 20% space, which is equivalent to 35%-40% under conventional conditions.

    .
    For most of the selected products, the logic of doubling the winning time is expected, especially for products with more than 6 companies bidding when participating in the bidding
    .

      Medical Network News on August 2nd that the fifth batch of national collections has been settled, and the provinces have successively issued documents to implement the results of the selection
    .
    On July 20, the Jiangxi Provincial Medical Security Bureau issued the "Notice on Launching the Fifth Batch of National-Organized Drug Centralized Procurement of Drugs Related to Online Procurement", requiring relevant selected companies to declare information online and confirm their distribution relationships
    .

     
      From the first batch to the fifth batch, Guocai has 218 products.
    There are a few products with good market expectations, policies, and volume in the first batch.
    The second to fourth batches are not many.
    The fifth batch is still There are a lot of them.
    There are at least 15 products that can be operated in each province without self-operated products
    .
     
      In recent years, the pressure on agents has been relatively high, and this is also true for most companies
    .
    Being able to "pass through the barriers" in the national procurement process gives the product a good market opportunity, and companies must choose high-quality partners
    .
    For agents, this is a once-in-a-lifetime opportunity, but many agents seem to be more than enthusiastic and insufficiently prepared
    .
     
      A rare opportunity
     
      1.
    National procurement + provincial/union belt volume + price linkage + "red, yellow and green" (the price of each province is divided
    .
    The red line is too high to enter the hospital; the yellow line can be used, but it must be monitored; the green line is not restricted) There must be a quantity expectation of 490 varieties.
    The provincial/union belt quantity will adopt an average of 20+ varieties in 2020, an average of 40+ varieties in the province/union in 2021, and 200+ varieties in the Guangdong Grand Alliance.
    The accumulation of this order of magnitude will result in increasingly stringent prices.
    "Assault" blind spots make it difficult for most products to have conventional policies
    .

     
      The quantity of various concepts, whether it is national or non-over-reviewed provincial/union mining, is a general trend within a period of time, and the future fate of similar products can be foreseen
    .
     
      Under this trend, there are fewer and fewer products that can have high-quality cooperation opportunities, but the market is still there, and there are no fewer agents
    .
    Whether the present is an opportunity depends not only on the present, but also on the future trend
    .

     
      2.
    The timeliness of making new medicines for old medicines.
    It is undeniable that new medicines for old medicines (classic return) can bring many opportunities, but except for products that can enter the list of shortage medicines, the market opportunities for other products are temporary
    .
     
      This temporaryity can be long or short, and it is difficult for these products to become mainstream in the market
    .
    Although compared with innovative drugs, these products have low cost and high controllability, but there are fewer and fewer operability products, and some products "play and crash"
    .

     
      The old medicines are newly made from chemical medicines to Chinese patent medicines, from the products of the 1990s to the 1980s, and now they are digging for the products of the 1960s and 1970s.
    If they continue to dig, they will go back and forth
    .
     
      3.
    The inaccessibility of innovation Most of the products of leading companies and innovative companies are self-operated
    .
    From the agency's point of view, the availability of innovative products is getting lower and lower.
    After all, innovative drugs are not something you can do if you want to
    .

     
      At present, there are not many innovative products in the chemical medicine category that have agency attributes.
    Even if the products approved every year are in the second and third categories, few companies do the agency model, and even if they do, it is a terminal cooperation model
    .
     
      With large investment in innovation, high risks, long cycles, and low probability, once there is a high-quality track, with the blessing of the capital side, it will soon become a "red sea"
    .
    From the perspectives of dosage form, compound prescription, route of administration, adding device, etc.
    , the endless "seventy-two changes" have almost nothing to do with small businesses
    .

     
      4.
    Difficulty of Chinese patent medicines.
    Change some Chinese patent medicines to beautiful packaging, circle a bunch of indications, and list the advantages of the market, but there are really not many who can turn out the waves.
    They are more immersed in their own "ideal country.
    " Inside
    .
     
      Most Chinese patent medicines are effective, with a wide range of indications, many manufacturers, optimistic market prospects, policy support, adequate Chinese medicine theory, and cruel market performance speaks for itself.
    Among the tens of thousands of approvals, those who stand out are only rare
    .
     
      To sum up, the high-quality cooperation bid won by the national mining company is definitely a good opportunity and should not be missed
    .
     
      Agent Baitai
     
      It is precisely because the fifth batch of Guocai Ke's high-quality cooperation products are not bad, the market has rippled, so that a lot of agents have rekindled the fire of hope, and they have shown everything
    .
     
      1.
    Tiger type (strong strength, understanding of the market, and macro vision) These agents often become the "head distributors" of the market in a certain field (treatment), holding a lot of products, and there are many large products.
    One of the goals that agency enterprises hope to cooperate with
    .
     
      They have a wealth of experience, strong business capabilities, a direct sales team and a distribution network, understand the general market trends, and can judge the product’s "vitality + market power"; they have a deep understanding of the category, and consider the terminal rational use of drugs, DRGs, and medication guidelines , Product features, instead of just talking about "who I know" and "how much space is there"; dare to make a move, dare to make a price, and know how to grasp the added value that high-quality cooperative products can bring under the opportunity of national sourcing.
    This is not just a matter of profit.
    But it can bring a series of market resources and opportunities to dominate in a certain field; data, capital, and market are fully prepared, full of sincerity, reasonable and well-founded
    .
     
      2.
    Black bear type These agents have certain or very strong strength, but they have lived in the past and have not yet emerged from the "comfort zone"
    .
     
      Their minds always revolve around 4 times space and 5 times space.
    When you talk about 3 times space, his expression reveals the following meaning: "With this little space, you still dare to talk to me for business? You don't know me.
    Don’t make varieties that are not 4 times larger? Don’t pick up varieties that are not over 100 million?"
     
      You talk to him about major trends, national policies, end-use drugs, product characteristics, and similar patterns.
    He just said: "High space can overwhelm everything
    .
    "
     
      As soon as the manufacturer wanted to talk about the situation of Guocai, he said to you: "I know, I have received a lot of Guodian products, and the space is good.
    Then, the terminal is not as you think, and the high-multiplier is not ideal.
    You can't do this
    .
    "
     
      They want money and money, and some people, but there is no way to talk with you on the same channel.
    Some things must be experienced, deeply experienced, and experienced.
    Only after suffering a loss can the three views be consistent
    .
    The typical "hibernation period" of such agents is too long, and some tiger-type agents have already occupied the territory.
    Judging from the general market trend, he has not yet woken up
    .

     
      3.
    Fish-catching type.
    This kind of agent is based on the principle of "there is no jujube but one shot".
    When encountering people who don't understand the market, they bombarded and talked about the little manager, and they basically succeeded.

    .
     
      They lack a macro understanding of the product and a lack of in-depth understanding of the market.
    When asked how big the product can be in a certain market, he said: "It's a lot, but a lot
    .
    " In contrast, he said: "Whose products are well sold and sold well
    .
    "
     
      Such agents know a little bit about the market, products, and trends, but they don't pay enough attention to their psychology and preparation
    .
     
      4.
    Peacock type.
    Such agents like to display "feathers"
    .
    The bigwigs of the rivers and lakes all have a glorious history.
    Speaking of the past, they can come back to life, and they are brilliant
    .
    Nowadays, market information is basically transparent, and there may be some information asymmetry, but there is no information that cannot be asked.
    The tiger has never been called a hunting dog, and the eagle has never been mistaken for a squab
    .
    Behind the beauty is real strength, not history
    .
     
      5.
    Wild wolf type.
    This kind of agents generally take part of the area or take part of the terminal, follow closely, bite to death, sincere, have the strength in the area, and have the vision of the provincial agent
    .
     
      After all, most of the agents are regional agents, and the provincial generations are also divided into levels.
    The first grade with annual sales of more than 1 billion yuan, the first grade with annual sales of more than 300 million yuan, the overall scale of less than 100 million provincial agents can only be called Total generation
    .
     
      However, among the provincial generations with annual sales of 100 million yuan, the new generation (post-90s and some post-80s) are absolutely motivated.
    They have a yearning for medicine and freedom of wealth.
    This is also when many companies choose agents .
    I prefer to talk more about the reasons with the new generation
    .
     
      Time never comes
     
      The era of meager profit has come for several years
    .
    Starting in 2019, how many varieties of the top 500 catalogs have not been included in the collection? Under the Guangdong Grand Alliance mechanism (combination of dosage forms and specifications), how much room does Group B have? How many products with reference preparations under the country still have a high-space policy? How long is the life cycle of a product that is not referenced or not evaluated? The market is still that market, and the product is still that product, but the opportunity is no longer the original opportunity
    .

     
      Varieties such as fosfomycin sodium, oxacillin, and mezacillin have been rapidly emerging, and markets such as cefminox and cefotaxime are responding quickly, but there are still several products that are not included in the national procurement, even if they are not in the fifth batch.
    In the catalog, the sixth and seventh batches may still be included.
    When the quantity is large, local and alliances will still be included.
    "Those who do not break the situation will still exist" (the monopoly will not be broken, and there will still be companies entering afterwards.
    Monopoly situation)
    .
     
      At this stage, acting as an agent for a non-exclusive product, if it can cover more than 40% of the terminals, it is considered a fairy-level figure of the agent
    .
    For Guocai products, if 50% of the quota is exempted from development, 30% of new accounts will reach the limit
    .
    Some specialized products and products with strong departmental characteristics can basically have more than 70% to 90% of the reported volume (development-free), and what the agent has to do is nothing more than an increase
    .
    Compared with each other, which one is easier?
     
      It can be understood that if there is a 10% space for the agent’s policy for national procurement products, it is equivalent to 20% under normal conditions; the national procurement policy gives 20% space, which is equivalent to 35%-40% under conventional conditions.

    .
    For most of the selected products, the logic of doubling the winning time is expected, especially for products with more than 6 companies bidding when participating in the bidding
    .

      Medical Network News on August 2nd that the fifth batch of national collections has been settled, and the provinces have successively issued documents to implement the results of the selection
    .
    On July 20, the Jiangxi Provincial Medical Security Bureau issued the "Notice on Launching the Fifth Batch of National-Organized Drug Centralized Procurement of Drugs Related to Online Procurement", requiring relevant selected companies to declare information online and confirm their distribution relationships
    .

     
      From the first batch to the fifth batch, Guocai has 218 products.
    There are a few products with good market expectations, policies, and volume in the first batch.
    The second to fourth batches are not many.
    The fifth batch is still There are a lot of them.
    There are at least 15 products that can be operated in each province without self-operated products
    .
     
      In recent years, the pressure on agents has been relatively high, and this is also true for most companies
    .
    Being able to "pass through the barriers" in the national procurement process gives the product a good market opportunity, and companies must choose high-quality partners
    .
    For agents, this is a once-in-a-lifetime opportunity, but many agents seem to be more than enthusiastic and insufficiently prepared
    .
     
      A rare opportunity
      A rare opportunity
     
      1.
    National procurement + provincial/union belt volume + price linkage + "red, yellow and green" (the price of each province is divided
    .
    The red line is too high to enter the hospital; the yellow line can be used, but it must be monitored; the green line is not restricted) There must be a quantity expectation of 490 varieties.
    The provincial/union belt quantity will adopt an average of 20+ varieties in 2020, an average of 40+ varieties in the province/union in 2021, and 200+ varieties in the Guangdong Grand Alliance.
    The accumulation of this order of magnitude will result in increasingly stringent prices.
    "Assault" blind spots make it difficult for most products to have conventional policies
    .

     
      The quantity of various concepts, whether it is national or non-over-reviewed provincial/union mining, is a general trend within a period of time, and the future fate of similar products can be foreseen
    .
     
      Under this trend, there are fewer and fewer products that can have high-quality cooperation opportunities, but the market is still there, and there are no fewer agents
    .
    Whether the present is an opportunity depends not only on the present, but also on the future trend
    .

     
      2.
    The timeliness of making new medicines for old medicines.
    It is undeniable that new medicines for old medicines (classic return) can bring many opportunities, but except for products that can enter the list of shortage medicines, the market opportunities for other products are temporary
    .
     
      This temporaryity can be long or short, and it is difficult for these products to become mainstream in the market
    .
    Although compared with innovative drugs, these products have low cost and high controllability, but there are fewer and fewer operability products, and some products "play and crash"
    .

     
      The old medicines are newly made from chemical medicines to Chinese patent medicines, from the products of the 1990s to the 1980s, and now they are digging for the products of the 1960s and 1970s.
    If they continue to dig, they will go back and forth
    .
     
      3.
    The inaccessibility of innovation Most of the products of leading companies and innovative companies are self-operated
    .
    From the agency's point of view, the availability of innovative products is getting lower and lower.
    After all, innovative drugs are not something you can do if you want to
    .

     
      At present, there are not many innovative products in the chemical medicine category that have agency attributes.
    Even if the products approved every year are in the second and third categories, few companies do the agency model, and even if they do, it is a terminal cooperation model
    .
     
      With large investment in innovation, high risks, long cycles, and low probability, once there is a high-quality track, with the blessing of the capital side, it will soon become a "red sea"
    .
    From the perspectives of dosage form, compound prescription, route of administration, adding device, etc.
    , the endless "seventy-two changes" have almost nothing to do with small businesses
    .

     
      4.
    Difficulty of Chinese patent medicines.
    Change some Chinese patent medicines to beautiful packaging, circle a bunch of indications, and list the advantages of the market, but there are really not many who can turn out the waves.
    They are more immersed in their own "ideal country.
    " Inside
    .
     
      Most Chinese patent medicines are effective, with a wide range of indications, many manufacturers, optimistic market prospects, policy support, adequate Chinese medicine theory, and cruel market performance speaks for itself.
    Among the tens of thousands of approvals, those who stand out are only rare
    .
    Chinese Medicine Chinese Medicine Chinese Medicine
     
      To sum up, the high-quality cooperation bid won by the national mining company is definitely a good opportunity and should not be missed
    .
     
      Agent Baitai
      Agent Baitai
     
      It is precisely because the fifth batch of Guocai Ke's high-quality cooperation products are not bad, the market has rippled, so that a lot of agents have rekindled the fire of hope, and they have shown everything
    .
     
      1.
    Tiger type (strong strength, understanding of the market, and macro vision) These agents often become the "head distributors" of the market in a certain field (treatment), holding a lot of products, and there are many large products.
    One of the goals that agency enterprises hope to cooperate with
    .
     
      They have a wealth of experience, strong business capabilities, a direct sales team and a distribution network, understand the general market trends, and can judge the product’s "vitality + market power"; they have a deep understanding of the category, and consider the terminal rational use of drugs, DRGs, and medication guidelines , Product features, instead of just talking about "who I know" and "how much space is there"; dare to make a move, dare to make a price, and know how to grasp the added value that high-quality cooperative products can bring under the opportunity of national sourcing.
    This is not just a matter of profit.
    But it can bring a series of market resources and opportunities to dominate in a certain field; data, capital, and market are fully prepared, full of sincerity, reasonable and well-founded
    .
     
      2.
    Black bear type These agents have certain or very strong strength, but they have lived in the past and have not yet emerged from the "comfort zone"
    .
     
      Their minds always revolve around 4 times space and 5 times space.
    When you talk about 3 times space, his expression reveals the following meaning: "With this little space, you still dare to talk to me for business? You don't know me.
    Don’t make varieties that are not 4 times larger? Don’t pick up varieties that are not over 100 million?"
     
      You talk to him about major trends, national policies, end-use drugs, product characteristics, and similar patterns.
    He just said: "High space can overwhelm everything
    .
    "
     
      As soon as the manufacturer wanted to talk about the situation of Guocai, he said to you: "I know, I have received a lot of Guodian products, and the space is good.
    Then, the terminal is not as you think, and the high-multiplier is not ideal.
    You can't do this
    .
    "
     
      They want money and money, and some people, but there is no way to talk with you on the same channel.
    Some things must be experienced, deeply experienced, and experienced.
    Only after suffering a loss can the three views be consistent
    .
    The typical "hibernation period" of such agents is too long, and some tiger-type agents have already occupied the territory.
    Judging from the general market trend, he has not yet woken up
    .

     
      3.
    Fish-catching type.
    This kind of agent is based on the principle of "there is no jujube but one shot".
    When encountering people who don't understand the market, they bombarded and talked about the little manager, and they basically succeeded.

    .
     
      They lack a macro understanding of the product and a lack of in-depth understanding of the market.
    When asked how big the product can be in a certain market, he said: "It's a lot, but a lot
    .
    " In contrast, he said: "Whose products are well sold and sold well
    .
    "
     
      Such agents know a little bit about the market, products, and trends, but they don't pay enough attention to their psychology and preparation
    .
    Mental mental mental
     
      4.
    Peacock type.
    Such agents like to display "feathers"
    .
    The bigwigs of the rivers and lakes all have a glorious history.
    Speaking of the past, they can come back to life, and they are brilliant
    .
    Nowadays, market information is basically transparent, and there may be some information asymmetry, but there is no information that cannot be asked.
    The tiger has never been called a hunting dog, and the eagle has never been mistaken for a squab
    .
    Behind the beauty is real strength, not history
    .
     
      5.
    Wild wolf type.
    This kind of agents generally take part of the area or take part of the terminal, follow closely, bite to death, sincere, have the strength in the area, and have the vision of the provincial agent
    .
     
      After all, most of the agents are regional agents, and the provincial generations are also divided into levels.
    The first grade with annual sales of more than 1 billion yuan, the first grade with annual sales of more than 300 million yuan, the overall scale of less than 100 million provincial agents can only be called Total generation
    .
     
      However, among the provincial generations with annual sales of 100 million yuan, the new generation (post-90s and some post-80s) are absolutely motivated.
    They have a yearning for medicine and freedom of wealth.
    This is also when many companies choose agents .
    I prefer to talk more about the reasons with the new generation
    .
    Pharmaceutical medicine pharmaceutical agent proxy agent
     
      Time never comes
      Time never comes
     
      The era of meager profit has come for several years
    .
    Starting in 2019, how many varieties of the top 500 catalogs have not been included in the collection? Under the Guangdong Grand Alliance mechanism (combination of dosage forms and specifications), how much room does Group B have? How many products with reference preparations under the country still have a high-space policy? How long is the life cycle of a product that is not referenced or not evaluated? The market is still that market, and the product is still that product, but the opportunity is no longer the original opportunity
    .

     
      Varieties such as fosfomycin sodium, oxacillin, and mezacillin have been rapidly emerging, and markets such as cefminox and cefotaxime are responding quickly, but there are still several products that are not included in the national procurement, even if they are not in the fifth batch.
    In the catalog, the sixth and seventh batches may still be included.
    When the quantity is large, local and alliances will still be included.
    "Those who do not break the situation will still exist" (the monopoly will not be broken, and there will still be companies entering afterwards.
    Monopoly situation)
    .
    Enterprise business enterprise
     
      At this stage, acting as an agent for a non-exclusive product, if it can cover more than 40% of the terminals, it is considered a fairy-level figure of the agent
    .
    For Guocai products, if 50% of the quota is exempted from development, 30% of new accounts will reach the limit
    .
    Some specialized products and products with strong departmental characteristics can basically have more than 70% to 90% of the reported volume (development-free), and what the agent has to do is nothing more than an increase
    .
    Compared with each other, which one is easier?
     
      It can be understood that if there is a 10% space for the agent’s policy for national procurement products, it is equivalent to 20% under normal conditions; the national procurement policy gives 20% space, which is equivalent to 35%-40% under conventional conditions.

    .
    For most of the selected products, the logic of doubling the winning time is expected, especially for products with more than 6 companies bidding when participating in the bidding
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.